Description:
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with
IMCgp100 as a single agent in patients with metastatic uveal melanoma (mUM). According to
this regimen, all patients in the trial will receive 2 weekly doses of IMCgp100 at a dose
level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose
escalation will commence at the third weekly dose at C1D15. The Phase I testing of the
intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal
plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter .
Title
- Brief Title: A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
- Official Title: A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma
Clinical Trial IDs
- ORG STUDY ID:
IMCgp100-102
- NCT ID:
NCT02570308
Conditions
Interventions
Drug | Synonyms | Arms |
---|
IMCgp100 | | Dose escalation |
Purpose
IMCgp100-102 is a Phase I/II study of the weekly intra-patient escalation dose regimen with
IMCgp100 as a single agent in patients with metastatic uveal melanoma (mUM). According to
this regimen, all patients in the trial will receive 2 weekly doses of IMCgp100 at a dose
level below the identified weekly recommended Phase II dose (RP2D-QW) and then a dose
escalation will commence at the third weekly dose at C1D15. The Phase I testing of the
intra-patient escalation dosing regimen is designed to achieve a higher exposure and maximal
plasma concentration of IMCgp100 after doses at Cycle 1 Day 15 (C1D15) and thereafter .
Detailed Description
This is a Phase I/II clinical study of IMCgp100 in patients with advanced uveal melanoma.
This is a Phase I/II study of IMCgp100 administered on a weekly basis with an intra-patient
escalation dosing regimen. The intra-patient escalation occurs at the third weekly dose on
Cycle 1 Day 15 (C1D15). According to this regimen, all patients in the trial will receive 2
weekly doses of IMCgp100 at a dose level below the identified weekly recommended Phase II
dose (RP2D-QW) and then a dose escalation will commence at the third weekly dose at C1D15
with the goal to achieve a long-term dosing regimen at a dose higher than that identified for
the straight weekly dosing regimen (RP2D-QW). The dose escalation will identify the
intra-patient escalation regimen (RP2D-IE).
The Phase I portion of the study was a standard 3+3 dose escalation design. The Phase 1
portion of the study is now complete. The recommended Phase II dose of the intra-patient
escalation dose regimen (RP2D-IE) was identified and the 2 expansion cohorts in metastatic
uveal melanoma will be completed. The cohorts will enroll patients with metastatic uveal
melanoma and are defined based on prior therapy The expansion portion will enroll
approximately 150 patients.
Trial Arms
Name | Type | Description | Interventions |
---|
Dose escalation | Experimental | Dose escalation cohorts of the intra-patient escalation regimen. This arm is closed | |
Dose expansion | Experimental | Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen | |
Eligibility Criteria
Inclusion Criteria:
1. Male or female patients age ≥ 18 years of age at the time of informed consent
2. Ability to provide and understand written informed consent prior to any study
procedures
3. Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma (mUM)
4. Surgically sterile patients or patients of child-bearing potential who agree to use
highly effective methods of contraception during study dosing and for 6 months after
last dose of study drug
5. Human leukocyte antigen (HLA)-A*0201 positive
6. ECOG Performance Status of 0 or 1 at Screening
7. Patients in Phase 2 will include patients with previously treated uveal melanoma in
the metastatic setting
Exclusion Criteria:
1. Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS
metastases that require doses of corticosteroids.
2. History of severe hypersensitivity reactions to other biologic drugs or monoclonal
antibodies
3. Patient with any out-of-range laboratory values.
4. Clinically significant cardiac disease or impaired cardiac function.
5. Active infection requiring systemic antibiotic therapy.
6. Known history of HIV infection.
7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional
protocol.
8. Patients receiving systemic treatment with systemic steroid therapy or any other
immunosuppressive medication at any dose level that would interfere with the action of
the study drugs in the opinion of the investigator
9. Malignant disease, other than that being treated in this study.
10. Any medical condition that would, in the investigator's judgment, prevent the
patient's participation in the clinical study due to safety concerns, compliance with
clinical study procedures or interpretation of study results
11. Presence of NCI CTCAE ≥ grade 2 toxicity (except alopecia, peripheral neuropathy and
ototoxicity, which are excluded if ≥ NCI CTCAE grade 3) due to prior cancer therapy
12. Pregnant, likely to become pregnant, or lactating women.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Phase 1 Recommended phase 2 dose of the intra-patient escalation regimen (RP2D-IE) |
Time Frame: | 1 years |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Objective response rate (Phase 1) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Progression free survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Overall survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Duration of response |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Time to response |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Minor response rate |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Number of treatment dose interruptions and reductions |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Area under the plasma concentration-time curve (AUC) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | Area under the plasma concentration-time curve (AUC) |
Time Frame: | 3 weeks |
Safety Issue: | |
Description: | |
Measure: | The maximum observed plasma drug concentration after single dose administration (Cmax) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Measure: | The time to reach maximum plasma concentration (Tmax) |
Time Frame: | 3 weeks |
Safety Issue: | |
Description: | |
Measure: | The elimination half-life (t1/2) |
Time Frame: | 3 weeks |
Safety Issue: | |
Description: | |
Measure: | Incidence of anti-IMCgp100 antibody formation |
Time Frame: | 2 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Immunocore Ltd |
Trial Keywords
- Tebentafusp
- IMCgp100
- gp100
- metastatic melanoma
- ImmTAC
- Immunotherapy
- Bispecific T cell receptor fusion protein
- Immune mobilizing monoclonal T cell receptor
- against cancer
- UM
- mUM
Last Updated
April 9, 2021